GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Changzhou Qianhong Biopharma Co Ltd (SZSE:002550) » Definitions » Piotroski F-Score

Changzhou Qianhong Biopharma Co (SZSE:002550) Piotroski F-Score : 7 (As of Apr. 22, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Changzhou Qianhong Biopharma Co Piotroski F-Score?

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Changzhou Qianhong Biopharma Co has an F-score of 9. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Changzhou Qianhong Biopharma Co's Piotroski F-Score or its related term are showing as below:

SZSE:002550' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 8
Current: 7

During the past 13 years, the highest Piotroski F-Score of Changzhou Qianhong Biopharma Co was 8. The lowest was 3. And the median was 6.


Changzhou Qianhong Biopharma Co Piotroski F-Score Historical Data

The historical data trend for Changzhou Qianhong Biopharma Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Changzhou Qianhong Biopharma Co Piotroski F-Score Chart

Changzhou Qianhong Biopharma Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 6.00 5.00 7.00 -

Changzhou Qianhong Biopharma Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 7.00 7.00 - -

Competitive Comparison of Changzhou Qianhong Biopharma Co's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Changzhou Qianhong Biopharma Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Changzhou Qianhong Biopharma Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Changzhou Qianhong Biopharma Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Changzhou Qianhong Biopharma Co's Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar25) TTM:Last Year (Mar24) TTM:
Net Income was 78.684 + 126.793 + 46.447 + 160.968 = ¥413 Mil.
Cash Flow from Operations was 113.085 + 166.556 + 63.959 + 71.512 = ¥415 Mil.
Revenue was 394.494 + 352.007 + 318.64 + 450.88 = ¥1,516 Mil.
Gross Profit was 205.853 + 201.434 + 184.856 + 245.259 = ¥837 Mil.
Average Total Assets from the begining of this year (Mar24)
to the end of this year (Mar25) was
(2728.721 + 2630.283 + 2762.272 + 2830.441 + 2948.304) / 5 = ¥2780.0042 Mil.
Total Assets at the begining of this year (Mar24) was ¥2,729 Mil.
Long-Term Debt & Capital Lease Obligation was ¥0 Mil.
Total Current Assets was ¥1,858 Mil.
Total Current Liabilities was ¥182 Mil.
Net Income was 33.079 + 78.829 + -15.994 + 104.108 = ¥200 Mil.

Revenue was 448.537 + 409.185 + 348.328 + 461.101 = ¥1,667 Mil.
Gross Profit was 203.069 + 187.61 + 155.538 + 245.033 = ¥791 Mil.
Average Total Assets from the begining of last year (Mar23)
to the end of last year (Mar24) was
(3066.259 + 2923.922 + 2738.222 + 2766.081 + 2728.721) / 5 = ¥2844.641 Mil.
Total Assets at the begining of last year (Mar23) was ¥3,066 Mil.
Long-Term Debt & Capital Lease Obligation was ¥0 Mil.
Total Current Assets was ¥1,580 Mil.
Total Current Liabilities was ¥208 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Changzhou Qianhong Biopharma Co's current Net Income (TTM) was 413. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Changzhou Qianhong Biopharma Co's current Cash Flow from Operations (TTM) was 415. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar24)
=412.892/2728.721
=0.15131338

ROA (Last Year)=Net Income/Total Assets (Mar23)
=200.022/3066.259
=0.06523324

Changzhou Qianhong Biopharma Co's return on assets of this year was 0.15131338. Changzhou Qianhong Biopharma Co's return on assets of last year was 0.06523324. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Changzhou Qianhong Biopharma Co's current Net Income (TTM) was 413. Changzhou Qianhong Biopharma Co's current Cash Flow from Operations (TTM) was 415. ==> 415 > 413 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0/2780.0042
=0

Gearing (Last Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=0/2844.641
=0

Changzhou Qianhong Biopharma Co's gearing of this year was 0. Changzhou Qianhong Biopharma Co's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar25)=Total Current Assets/Total Current Liabilities
=1858.267/181.827
=10.21997283

Current Ratio (Last Year: Mar24)=Total Current Assets/Total Current Liabilities
=1579.634/208.266
=7.58469457

Changzhou Qianhong Biopharma Co's current ratio of this year was 10.21997283. Changzhou Qianhong Biopharma Co's current ratio of last year was 7.58469457. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Changzhou Qianhong Biopharma Co's number of shares in issue this year was 1249.755. Changzhou Qianhong Biopharma Co's number of shares in issue last year was 1258.865. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=837.402/1516.021
=0.55236834

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=791.25/1667.151
=0.47461208

Changzhou Qianhong Biopharma Co's gross margin of this year was 0.55236834. Changzhou Qianhong Biopharma Co's gross margin of last year was 0.47461208. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar24)
=1516.021/2728.721
=0.55557934

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar23)
=1667.151/3066.259
=0.54370847

Changzhou Qianhong Biopharma Co's asset turnover of this year was 0.55557934. Changzhou Qianhong Biopharma Co's asset turnover of last year was 0.54370847. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+1+1+1
=9

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Changzhou Qianhong Biopharma Co has an F-score of 9. It is a good or high score, which usually indicates a very healthy situation.

Changzhou Qianhong Biopharma Co  (SZSE:002550) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Changzhou Qianhong Biopharma Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Changzhou Qianhong Biopharma Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Changzhou Qianhong Biopharma Co Business Description

Traded in Other Exchanges
N/A
Address
Number 90 Changjiang Middle Road, Xinbei distract, Jiangsu Province, Changzhou, CHN, 213022
Changzhou Qianhong Biopharma Co Ltd engages in the research and development, production, and sale of biopharmaceutical products with the focus on polysaccharides and enzymes in China. The company provides various products, including heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium for use as anticoagulants; pancreatin for use as a digestive agent; asparaginase for use as an antineoplastic agent; and kallidinogenase kallikrein and heparinoid.
Executives
Huang Jie Executives
Wang Ke Directors, executives
Jiang Wen Qun Supervisors
Zou Shao Bo Executives
Wei Li Jun Executives
Mei Chun Wei Executives
Zhou Xiang Directors, executives
Zhao Gang Director
Ye Hong Ping Executives
Liu Jun Director
Fan Yong Executives
Jiang Jian Ping Supervisors
Wang Yao Fang Director
Hai Tao Directors, executives
Wang Yi Director

Changzhou Qianhong Biopharma Co Headlines

No Headlines